(Updated - September 22, 2021 5:26 AM EDT)

Goldman Sachs analyst Paul Choi downgraded FibroGen (NASDAQ: FGEN) from Neutral ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE